Avacta Group PLC Director/PDMR Shareholding (5787H)

TIDMAVCT

RNS Number : 5787H

Avacta Group PLC

13 March 2018

13 March 2018

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Director/PDMR Shareholding

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today purchased 35,800 ordinary shares of 10p each ("Ordinary Shares") at a price of 41.92p per Ordinary Share.

Following this transaction, Dr Smith's total beneficial interest in the Group is 606,309 Ordinary Shares, representing approximately 0.9% of Avacta's issued share capital. In addition, Alastair Smith has a joint interest in 1,640,000 shares in the share capital of the Company; such shares are jointly held by certain Directors individually and Avacta Group Trustee Limited in its capacity as trustee of The Avacta Employees' Share Trust.

Enquiries:

 
     Avacta Group plc                            Tel: +44 (0) 
      Alastair Smith, Chief Executive             844 414 0452 
      Officer                                     www.avacta.com 
      Tony Gardiner, Chief Financial 
      Officer 
     finnCap Ltd                                 Tel: +44 (0) 
      Geoff Nash / Giles Rolls - Nominated        207 220 0500 
      Adviser                                     www.finncap.com 
      Tim Redfern / Alice Lane / Nikita 
      Jain - Corporate Broking 
                                                  Tel: +44 (0) 
      WG Partners                                 203 705 9318 
      David Wilson                                Tel: +44 (0) 
      Nigel Barnes                                203 705 9217 
      Claes Spang                                 www.wgpartners.co.uk 
     Yellow Jersey PR (Financial Media           Tel: [phone] 
      and IR)                                     947137 
      Sarah Hollins                               [e-mail] 
 

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
     1.       Details of the person discharging managerial 
               responsibilities / person closely associated 
-------  ---------------------------------------------------------------------------- 
     a)       Name                                 Alastair Smith 
-------  -----------------------------------  --------------------------------------- 
     2.       Reason for the Notification 
-------  ---------------------------------------------------------------------------- 
     a)       Position/status                      Chief Executive Officer 
-------  -----------------------------------  --------------------------------------- 
     b)       Initial notification/Amendment            Initial notification 
-------  -----------------------------------  --------------------------------------- 
 3.           Details of the issuer, emission allowance 
               market participant, auction platform, auctioneer 
               or auction monitor 
-------  ---------------------------------------------------------------------------- 
     a)       Name                                 Avacta Group Plc 
-------  -----------------------------------  --------------------------------------- 
     b)       LEI                                  2138009U3EG31OPMGH36 
-------  -----------------------------------  --------------------------------------- 
 4.           Details of the transaction(s): section to 
               be repeated for (i) each type of instrument; 
               (ii) each type of transaction; (iii) each 
               date; and (iv) each place where transactions 
               have been conducted 
-------  ---------------------------------------------------------------------------- 
     a)       Description of                             Ordinary shares 
               the Financial                               of 10p 
               instrument, type 
               of instrument 
------- 
              Identification                       GB00BYYW9G87 
               code 
-------  -----------------------------------  --------------------------------------- 
     b)       Nature of the                              Purchase of ordinary shares 
               transaction 
-------  -----------------------------------  --------------------------------------- 
     c)       Price(s) and                              Price(s)           Volume(s) 
               volume(s)                            -----------------  -------------- 
                                                         41.92 pence        35,800 
                                                    -----------------  -------------- 
-------  -----------------------------------  --------------------------------------- 
     d)       Aggregated information: 
                *    Aggregated volume               See above 
 
 
                *    Price 
-------  -----------------------------------  --------------------------------------- 
     e)       Date of the transaction              13 March 2018 
-------  -----------------------------------  --------------------------------------- 
     f)       Place of the                         London Stock Exchange, AIM 
               transaction                          Market (XLON) 
-------  -----------------------------------  --------------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHFKNDKBBKDKND

(END) Dow Jones Newswires

March 13, 2018 08:02 ET (12:02 GMT)